Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology

Most of the guideline-recommended treatment strategies for patients with acute coronary syndromes have been tested in large randomised clinical trials. Still, a major challenge is represented by patients with acute myocardial infarction admitted with impending or established cardiogenic shock. Despite early revascularization the mortality of cardiogenic shock remains high and roughly half of patients do not survive until hospital discharge or 30-day follow-up. However, there is only limited evidence-based scientific knowledge in the cardiogenic shock setting. Therefore, recommendations and actual treatments are often based on retrospective or prospective registry data and extrapolations from randomised clinical trials in acute myocardial infarction patients without cardiogenic shock. This position statement will summarise the current consensus of the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock based on current evidence and will provide advice for clinical practice.

[1]  B. Giraudeau,et al.  Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm. , 2019, The New England journal of medicine.

[2]  H. Jneid,et al.  Temporal Trends and Outcomes of Mechanical Complications in Patients With Acute Myocardial Infarction. , 2019, JACC. Cardiovascular interventions.

[3]  J. Ornato,et al.  SCAI clinical expert consensus statement on the classification of cardiogenic shock , 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  Deepak L. Bhatt,et al.  Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. , 2019, Resuscitation.

[5]  G. Schuler,et al.  Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial , 2019, Circulation.

[6]  H. Thiele,et al.  Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial , 2019, Circulation.

[7]  W. O’Neill,et al.  Cardiac Shock Care Centers: JACC Review Topic of the Week. , 2018, Journal of the American College of Cardiology.

[8]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[9]  H. Thiele,et al.  One‐Year Outcomes after PCI Strategies in Cardiogenic Shock , 2018, The New England journal of medicine.

[10]  A. Mebazaa,et al.  Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. , 2018, Journal of the American College of Cardiology.

[11]  T. Friede,et al.  Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial , 2018, European heart journal.

[12]  Ajay K. Jain,et al.  Contemporary trends in cardiogenic shock: Incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group , 2018, European heart journal. Acute cardiovascular care.

[13]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[14]  H. Thiele,et al.  Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials , 2017, European heart journal.

[15]  H. Thiele,et al.  PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock , 2017, The New England journal of medicine.

[16]  E. Ohman,et al.  Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association , 2017, Circulation.

[17]  D. Burkhoff,et al.  Mechanical Circulatory Support Devices for Acute Right Ventricular Failure. , 2017, Circulation.

[18]  H. Thiele,et al.  Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction. , 2017, Journal of the American College of Cardiology.

[19]  G. Schuler,et al.  MILD HYPOTHERMIA IN CARDIOGENIC SHOCK COMPLICATING MYOCARDIAL INFARCTION: THE RANDOMIZED SHOCK-COOL PILOT TRIAL , 2017 .

[20]  J. Kjaergaard,et al.  The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[21]  J. Tijssen,et al.  Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. , 2017, Journal of the American College of Cardiology.

[22]  R. Erbel,et al.  Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE) , 2017, Thrombosis and Haemostasis.

[23]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[24]  H. Thiele,et al.  Interventional post-myocardial infarction ventricular septal defect closure: a systematic review of current evidence. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  G. Filippatos,et al.  Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology , 2016, European journal of heart failure.

[26]  J. Messenger,et al.  Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry. , 2016, JACC. Cardiovascular interventions.

[27]  E. Ohman,et al.  Management of cardiogenic shock. , 2015, European heart journal.

[28]  E. Omerovic,et al.  17-year trends in incidence and prognosis of cardiogenic shock in patients with acute myocardial infarction in western Sweden. , 2015, International journal of cardiology.

[29]  Richard Beale,et al.  Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine , 2014, Intensive Care Medicine.

[30]  Claude Guerin,et al.  High versus low blood-pressure target in patients with septic shock. , 2014, The New England journal of medicine.

[31]  J. Hochman,et al.  Mechanical circulatory support in cardiogenic shock. , 2014, European heart journal.

[32]  G. Schuler,et al.  Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial , 2013, The Lancet.

[33]  G. Schuler,et al.  Intraaortic balloon support for myocardial infarction with cardiogenic shock. , 2012, The New England journal of medicine.

[34]  N. Danchin,et al.  Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries. , 2012, European heart journal.

[35]  P. McCarthy,et al.  Surgical repair of ventricular septal defect after myocardial infarction: outcomes from the Society of Thoracic Surgeons National Database. , 2012, The Annals of thoracic surgery.

[36]  J. Haerting,et al.  Hemodynamic Effects of Intra-aortic Balloon Counterpulsation in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock: The Prospective, Randomized IABP Shock Trial , 2012, Shock.

[37]  P. Widimsky,et al.  Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study , 2011, Acute cardiac care.

[38]  J. Vincent,et al.  Comparison of dopamine and norepinephrine in the treatment of shock. , 2010, The New England journal of medicine.

[39]  C. Schneider,et al.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. , 2008, European heart journal.

[40]  R. Lidón,et al.  Changes in Hospital Mortality Rates in 425 Patients With Acute ST-Elevation Myocardial Infarction and Cardiac Rupture Over a 30-Year Period , 2008, Circulation.

[41]  Adnan Kastrati,et al.  A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. , 2008, Journal of the American College of Cardiology.

[42]  M. Pfisterer,et al.  Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock , 2008, Annals of Internal Medicine.

[43]  M. Enriquez-Sarano,et al.  Clinical Outcome After Surgical Correction of Mitral Regurgitation Due to Papillary Muscle Rupture , 2008, Circulation.

[44]  J. Nicholl,et al.  Noninvasive ventilation in acute cardiogenic pulmonary edema. , 2008, The New England journal of medicine.

[45]  Judith S. Hochman,et al.  Cardiogenic Shock: Current Concepts and Improving Outcomes , 2008, Circulation.

[46]  H. White,et al.  Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. , 2006, JAMA.

[47]  S. Assmann,et al.  Comparison of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting After Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results From the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Trial , 2005, Circulation.

[48]  T. LeJemtel,et al.  Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. , 2004, Journal of the American College of Cardiology.

[49]  Alan D. Lopez,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. , 2002, The New England journal of medicine.

[50]  M. Fishbein,et al.  Ventricular septal rupture after acute myocardial infarction. , 2002, The New England journal of medicine.

[51]  Karen Smith,et al.  Treatment of Comatose Survivors of Out-of-hospital Cardiac Arrest With Induced Hypothermia , 2003 .

[52]  S. Bernard,et al.  Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. , 2002, The New England journal of medicine.

[53]  Michael Holzer,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest , 2002 .

[54]  H. White,et al.  One-year survival following early revascularization for cardiogenic shock. , 2001, JAMA.

[55]  H. White,et al.  Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? , 2000, Journal of the American College of Cardiology.

[56]  H. White,et al.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.

[57]  J. López-Sendón,et al.  Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. , 1992, Journal of the American College of Cardiology.

[58]  M. Gotsman,et al.  Intraaortic balloon counterpulsation in acute myocardial infarction. , 1982, Israel journal of medical sciences.

[59]  T. Killip,et al.  Pathophysiology of Cardiogenic Shock: Quantification of Myocardial Necrosis, Clinical, Pathologic and Electrocardiographic Correlations , 1973, Circulation.

[60]  A. Markota,et al.  GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation. , 2018, Heart, lung & circulation.

[61]  G. Filippatos,et al.  Indications and practical approach to non-invasive ventilation in acute heart failure , 2018, European heart journal.

[62]  J. Messenger,et al.  Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction A , 2016 .

[63]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[64]  R. Mehta,et al.  Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? , 2010, American heart journal.